Search

Displaying results 4601 - 4610 of 5300 in total
  1. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    [L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots.

  2. Drug

    Viral Macrophage-Inflammatory Protein

    go.drugbank.com/drugs/DB15748
    Experimental

    Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus...

  3. Drug

    Stamulumab

    go.drugbank.com/drugs/DB05915
    Investigational

    MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.

  4. Drug

    Becocalcidiol

    go.drugbank.com/drugs/DB04891
    Investigational

    Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.

  5. Drug

    PH-284

    go.drugbank.com/drugs/DB05452
    Experimental

    Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages.

  6. Drug

    MX6

    go.drugbank.com/drugs/DB05789
    Experimental

    compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can

  7. Drug

    Spermine

    go.drugbank.com/drugs/DB00127
    InvestigationalNutraceutical

    Found in various tissues and organisms, it often acts as an essential growth factor in some bacterial species.

  8. Drug

    beta-Alanine

    go.drugbank.com/drugs/DB03107
    Investigational

    beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].

  9. Drug

    4'-Methylene-5,8,10-trideazaaminopterin

    go.drugbank.com/drugs/DB05616
    Investigational

    CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier

  10. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.